Home

WASHINGTON (Reuters) - Monsanto's genetically engineered, drought resistant corn is deregulated, the U.S. Agriculture Department said Thursday, clearing the variety for sale.

USDA approved the variety after reviewing environmental and risk assessments, public comments and research data from Monsanto.

Corn is the most widely grown U.S. crop and farmers grew 91.9 million acres of the feed grain ...

LONDON (Reuters) - Western generic drugmakers need to adapt to cope with rapid changes in the pharmaceuticals market that are blurring the distinctions between innovator companies and makers of cheaper copycat products.

That is the view of Claudio Albrecht, chief executive of Swiss-based Actavis, which struck a deal on Wednesday with QRxPharma to sell a new patented painkiller called MoxDuo that ...

LONDON/PARIS (Reuters) - Three of Europe's biggest drugmakers -- AstraZeneca , Novartis and Sanofi -- reported product setbacks on Tuesday, underlining the difficulties of developing new medicines to make up for those going off patent.

With the weakest pipeline of its European peers, AstraZeneca was hit hardest by a double blow to treatments for cancer and depression, which triggered $381.5 million ...

DEC 19 - Amgen Inc, the world's largest biotechnology company, and generic drugmaker Watson Pharmaceuticals Inc, said on Monday they will work together to develop and sell biosimilar versions of several biotech cancer drugs.

The companies, which plan to sell biosimilar products under a joint Amgen/Watson label, did not identify which drugs they are planning to develop cheaper versions ...

DEC 19 - Amgen Inc, the world's largest biotechnology company, and generic drugmaker Watson Pharmaceuticals Inc, said on Monday they will work together to develop and sell biosimilar versions of several biotech cancer drugs.

The companies, which plan to sell biosimilar products under a joint Amgen/Watson label, did not identify which drugs they are planning to develop cheaper versions ...

NEW YORK (Reuters) - The chief executive of Merck & Co on Tuesday defended his refusal to slash the drugmaker's $8 billion research budget and warned that global price constraints threaten the pharmaceutical industry's ability to innovate.

The drug industry is embroiled in a debate over whether companies are spending too much on research given a poor track record in ...

LONDON (Reuters) - AstraZeneca is cutting nearly a quarter of its U.S. sales force in a second wave of redundancies in as many months as it seeks to reduce costs.

Britain's second biggest drugmaker said on Wednesday it would cut about 1,150 sales representative and management jobs at a cost of between $50 million and $100 million, charged ...

LONDON (Reuters) - AstraZeneca is cutting nearly a quarter of its U.S. sales force in a second wave of redundancies in as many months as it seeks to reduce costs.

Britain's second biggest drugmaker said on Wednesday it would cut about 1,150 sales representative and management jobs at a cost of between $50 million and $100 million, charged ...

(Reuters) - AstraZeneca said it will cut about 1,150 U.S. sales jobs, and expects to take a related charge of about $50-$100 million in the fourth quarter.

The company said the job cuts, which will account for about 24 percent of the company's U.S. sales force, will not impact its 2011 earnings outlook.

Shares of the ...

LONDON (Reuters) - British scientists have made the first human embryonic stem cells of a high enough grade to use in patients and deposited them in a public stem cell bank for development in human trials by drug companies and researchers by 2014.

A team from King's College London said on Monday they were submitting two clinical-grade stem cell lines ...